CY1120880T1 - Δικυκλικη ενωση που περιεχει θειο - Google Patents
Δικυκλικη ενωση που περιεχει θειοInfo
- Publication number
- CY1120880T1 CY1120880T1 CY20181100858T CY181100858T CY1120880T1 CY 1120880 T1 CY1120880 T1 CY 1120880T1 CY 20181100858 T CY20181100858 T CY 20181100858T CY 181100858 T CY181100858 T CY 181100858T CY 1120880 T1 CY1120880 T1 CY 1120880T1
- Authority
- CY
- Cyprus
- Prior art keywords
- gabab
- schizophrenia
- diseases
- lower alkyl
- sulfur
- Prior art date
Links
- 229910052717 sulfur Inorganic materials 0.000 title abstract 3
- 239000011593 sulfur Substances 0.000 title abstract 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000000980 schizophrenia Diseases 0.000 abstract 3
- -1 bicyclic compound Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 150000003463 sulfur Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
[Πρόβλημα] Παροχή ένωσης που είναι χρήσιμη ως φαρμακευτική σύνθεση για πρόληψη ή/και θεραπεία ασθενειών όπως σχιζοφρένειας. [Επίλυση] Οι εφευρέτες ανέπτυξαν την παρούσα εφεύρεση κατά τη διερεύνηση φαρμακευτικής σύνθεσης που έχει αποτελέσματα ως θετικός αλλοστερικός ρυθμιστής GABAB (αποτελέσματα ως ΡΑΜ) για πρόληψη θεραπείας ασθενειών όπως σχιζοφρένειας και επιβεβαίωση ότι δικυκλική ένωση που περιέχει θείο έχει αποτελέσματα ως GABAB ΡΑΜ. Αυτή η δικυκλική ένωση που περιέχει θείο έχει αποτελέσματα ως GABAB ΡΑΜ και μπορεί να χρησιμοποιηθεί ως προληπτικός ή/και θεραπευτικός παράγων για ασθένειες όπως σχιζοφρένεια. (Στον τύπο, Χ αντιπροσωπεύει CH, R1 αντιπροσωπεύει κατώτερη αλκύλ, R2 αντιπροσωπεύει κατώτερη αλκύλ, R3 αντιπροσωπεύει -Η, R4 αντιπροσωπεύει -Η, δακτύλιος Α είναι δακτύλιος κυκλοεξανίου, RY αντιπροσωπεύει ομάδα που αντιπροσωπεύεται από τον τύπο (III), Υ αντιπροσωπεύει ΝΗ, κ.λπ., και RL αντιπροσωπεύει κατώτερη αλκύλ.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013216332 | 2013-10-17 | ||
| PCT/JP2014/077653 WO2015056771A1 (ja) | 2013-10-17 | 2014-10-17 | 含硫黄二環式化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120880T1 true CY1120880T1 (el) | 2020-05-29 |
Family
ID=52826697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100858T CY1120880T1 (el) | 2013-10-17 | 2018-08-14 | Δικυκλικη ενωση που περιεχει θειο |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US9051339B2 (el) |
| EP (1) | EP3059239B1 (el) |
| JP (1) | JP6477484B2 (el) |
| KR (1) | KR102248450B1 (el) |
| CN (1) | CN105636965B (el) |
| AR (1) | AR098070A1 (el) |
| AU (1) | AU2014335304B2 (el) |
| BR (1) | BR112016008654B8 (el) |
| CA (1) | CA2927518C (el) |
| CY (1) | CY1120880T1 (el) |
| DK (1) | DK3059239T3 (el) |
| EA (1) | EA029075B1 (el) |
| ES (1) | ES2685070T3 (el) |
| HK (1) | HK1220192A1 (el) |
| HR (1) | HRP20181183T1 (el) |
| HU (1) | HUE040208T2 (el) |
| IL (1) | IL244953B (el) |
| LT (1) | LT3059239T (el) |
| MX (1) | MX367857B (el) |
| MY (1) | MY177271A (el) |
| NZ (1) | NZ719149A (el) |
| PH (1) | PH12016500625B1 (el) |
| PL (1) | PL3059239T3 (el) |
| PT (1) | PT3059239T (el) |
| RS (1) | RS57532B1 (el) |
| SA (1) | SA516370956B1 (el) |
| SG (1) | SG11201602926UA (el) |
| SI (1) | SI3059239T1 (el) |
| TW (1) | TWI648281B (el) |
| UA (1) | UA116042C2 (el) |
| WO (1) | WO2015056771A1 (el) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU231058B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt. | Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| CN111886127B (zh) | 2018-02-06 | 2022-07-26 | 株式会社瑞光 | 伸缩片材、使用该伸缩片材的一次性穿戴物品及其制造方法 |
| EP3845230B1 (en) * | 2018-08-31 | 2023-07-12 | Astellas Pharma Inc. | Pharmaceutical composition for oral administration |
| TW202220992A (zh) | 2020-08-05 | 2022-06-01 | 匈牙利商羅特格登公司 | 具藥理活性之經雜環取代的吡唑并〔１，５－ａ〕嘧啶衍生物 |
| WO2023028519A2 (en) * | 2021-08-27 | 2023-03-02 | Astellas Pharma Global Development, Inc. | Methods of treating substance use disorder |
| WO2024048714A1 (ja) * | 2022-09-01 | 2024-03-07 | アステラス製薬株式会社 | ６－（４，４－ジメチルシクロヘキシル）－４－［（１，１－ジオキソ－１λ６－チオモルホリン－４－イル）メチル］－２－メチルチエノ［２，３－ｄ］ピリミジンまたはその塩の製造方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001097979A (ja) | 1999-07-28 | 2001-04-10 | Takeda Chem Ind Ltd | 縮合複素環化合物、その製造法および用途 |
| WO2002062803A1 (fr) | 2001-02-08 | 2002-08-15 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de thienopyrimidine |
| JP2002308882A (ja) * | 2001-02-08 | 2002-10-23 | Yamanouchi Pharmaceut Co Ltd | チエノピリミジン誘導体 |
| JP4677518B2 (ja) * | 2003-03-31 | 2011-04-27 | エピックス デラウェア， インコーポレイテッド | 新規ピペリジニルアミノ−チエノ［２，３−ｄ］ピリミジン化合物 |
| CA2544213A1 (en) * | 2003-10-28 | 2005-05-19 | Sepracor Inc. | Imidazo[1,2-a]pyridine anxiolytics |
| GB0416168D0 (en) | 2004-07-20 | 2004-08-18 | Vernalis Cambridge Ltd | Pyrmidothiophene compounds |
| GB0420719D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| ATE430751T1 (de) * | 2004-12-17 | 2009-05-15 | Hoffmann La Roche | Thienopyridinderivate als allostere gaba-b- enhancer |
| AU2007243457B2 (en) | 2006-04-26 | 2012-02-23 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
| WO2010103130A2 (en) | 2009-03-13 | 2010-09-16 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Novel bicyclic heterocycles |
| WO2011029054A1 (en) | 2009-09-04 | 2011-03-10 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| GB201015411D0 (en) | 2010-09-15 | 2010-10-27 | Univ Leuven Kath | Anti-cancer activity of novel bicyclic heterocycles |
-
2014
- 2014-10-16 TW TW103135823A patent/TWI648281B/zh active
- 2014-10-17 WO PCT/JP2014/077653 patent/WO2015056771A1/ja active Application Filing
- 2014-10-17 JP JP2015542677A patent/JP6477484B2/ja active Active
- 2014-10-17 PL PL14853825T patent/PL3059239T3/pl unknown
- 2014-10-17 EP EP14853825.9A patent/EP3059239B1/en active Active
- 2014-10-17 SI SI201430780T patent/SI3059239T1/en unknown
- 2014-10-17 SG SG11201602926UA patent/SG11201602926UA/en unknown
- 2014-10-17 ES ES14853825.9T patent/ES2685070T3/es active Active
- 2014-10-17 US US14/517,229 patent/US9051339B2/en active Active
- 2014-10-17 AR ARP140103875A patent/AR098070A1/es active IP Right Grant
- 2014-10-17 CN CN201480057239.0A patent/CN105636965B/zh active Active
- 2014-10-17 EA EA201690790A patent/EA029075B1/ru not_active IP Right Cessation
- 2014-10-17 BR BR112016008654A patent/BR112016008654B8/pt active IP Right Grant
- 2014-10-17 DK DK14853825.9T patent/DK3059239T3/en active
- 2014-10-17 LT LTEP14853825.9T patent/LT3059239T/lt unknown
- 2014-10-17 MX MX2016004944A patent/MX367857B/es active IP Right Grant
- 2014-10-17 PT PT14853825T patent/PT3059239T/pt unknown
- 2014-10-17 AU AU2014335304A patent/AU2014335304B2/en active Active
- 2014-10-17 UA UAA201605245A patent/UA116042C2/uk unknown
- 2014-10-17 KR KR1020167011628A patent/KR102248450B1/ko active IP Right Grant
- 2014-10-17 MY MYPI2016701379A patent/MY177271A/en unknown
- 2014-10-17 RS RS20180865A patent/RS57532B1/sr unknown
- 2014-10-17 HU HUE14853825A patent/HUE040208T2/hu unknown
- 2014-10-17 CA CA2927518A patent/CA2927518C/en active Active
- 2014-10-17 NZ NZ71914914A patent/NZ719149A/en unknown
-
2015
- 2015-04-17 US US14/689,748 patent/US9642852B2/en active Active
-
2016
- 2016-04-06 IL IL244953A patent/IL244953B/en active IP Right Grant
- 2016-04-06 PH PH12016500625A patent/PH12016500625B1/en unknown
- 2016-04-16 SA SA516370956A patent/SA516370956B1/ar unknown
- 2016-07-14 HK HK16108264.4A patent/HK1220192A1/zh unknown
-
2018
- 2018-07-26 HR HRP20181183TT patent/HRP20181183T1/hr unknown
- 2018-08-14 CY CY20181100858T patent/CY1120880T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120880T1 (el) | Δικυκλικη ενωση που περιεχει θειο | |
| CY1124330T1 (el) | Νευροδραστικα στεροειδη, συνθεσεις, και χρησεις αυτων | |
| CY1123246T1 (el) | Συνθεσεις και μεθοδοι για τη θεραπευτικη αντιμετωπιση διαταραχων του κνς | |
| PE20151781A1 (es) | Piridonamidas como moduladores de canales de sodio | |
| MA42109A (fr) | Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase | |
| UY33497A (es) | Derivados de espiro-piperidina como moduladores s1p | |
| EA201790024A1 (ru) | Модуляторы toll-подобных рецепторов для лечения вич | |
| UA107796C2 (en) | Tetracyclic compound | |
| DOP2015000289A (es) | Compuestos de 3,4-dihidroisoquinolin-2(1h)-ilo | |
| JO3466B1 (ar) | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 | |
| CR20130501A (es) | Derivados novedosos de cefalosporinas y composiciones farmacéuticas de estos | |
| MX2015010106A (es) | Moduladores de la proteina activadora de 5-lipoxigenasa. | |
| TN2015000018A1 (en) | 5-ht3 receptor antagonists | |
| MX2016007861A (es) | Compuestos de ácido dimetilbenzoico. | |
| BR112015029348A2 (pt) | inibidores da bace | |
| UY33496A (es) | Derivados heterociclicos fusionados como moduladores s1p | |
| UA115583C2 (uk) | Азетидинілоксифенілпіролідинові сполуки | |
| EA201590757A1 (ru) | Новые селективные модуляторы андрогенных рецепторов | |
| CL2021000421A1 (es) | Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende. | |
| EA201170997A1 (ru) | Производные индола в качестве противораковых агентов | |
| EA201600323A1 (ru) | Производные пиперазина и их применение в качестве лекарственного средства | |
| PH12018500668A1 (en) | Therapeutic compounds and methods of use thereof | |
| EA201690535A1 (ru) | 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2 | |
| EA201590729A1 (ru) | Производные 3,4-дизамещенного оксазолидинона и их применение в качестве ингибиторов кальцийактивируемых калиевых каналов | |
| MX2015010790A (es) | Derivados de anilina sustituidos con n-heteroarilo como antivirales de vhc. |